Eppendorf acquires life science firm DASGIP Group

Eppendorf has announced the acquisition of DASGIP Group, a leading life science firm with expertise in the fields of bioprocesses and information technology.

The purchased company, which has headquarters in Germany and the US, has been identified as a strategically important target for Eppendorf, with the deal closing on January 2nd 2012.

DASGIP has a strong reputation as a developer and manufacturer of parallel bioreactor systems and innovative control and analysis software, which will complement Eppendorf's existing New Brunswick product lines.

Moreover, the strategies and corporate cultures of the two companies have been identified as a strong fit for each other, meaning Eppendorf will be able to benefit from the introduction of complementary technical expertise and products.

Dr Dirk Ehlers, chief executive officer of Eppendorf, said: "They allow us to forge a comprehensive suite of products for bioprocess research applications … Furthermore, the advanced software concepts will position DASGIP as a strong Competence Centre in these fields."

This comes a year after the company completed its integration of all New Brunswick UK operations into its commercial activities.